Peptides for Weight Loss: Semaglutide, Tirzepatide and the GLP-1 Revolution

No molecule has captured public imagination quite like semaglutide. Known by the brand names Ozempic and Wegovy, this peptide has transformed obesity treatment and sparked a global debate touching medicine, ethics, and culture. But behind the sensational headlines, what does science actually say?

How GLP-1 peptides work

To understand semaglutide, you need to start with GLP-1 (Glucagon-Like Peptide-1). It's a peptide hormone naturally produced by L cells in the intestine after meals. Its role is simple but crucial: it signals to the brain that you've eaten enough.

Natural GLP-1 acts on three fronts. First, it slows gastric emptying, making you feel full longer. Second, it stimulates insulin production only when glucose levels are high, helping control blood sugar. Third, it acts on satiety centers in the hypothalamus, reducing appetite and the constant "background noise" of food in your head.

The problem with natural GLP-1 is that it's destroyed by enzymes within minutes. Semaglutide has been engineered to resist this degradation, maintaining the effect for about a week with a single injection.

Semaglutide: the real numbers

Semaglutide is probably the most studied drug of recent years. The STEP clinical trials (Semaglutide Treatment Effect in People with Obesity) produced unprecedented results in the history of obesity medicine.

In 68-week trials, patients lost an average of 15-17% of body weight. For a 100 kg person, that means 15-17 kg. A result no previous drug had ever achieved.

But average numbers hide significant variability. About 30% of participants lose more than 20% of their weight. Another 10-15% respond poorly or not at all. Genetics play a significant role in individual response.

Side effects. Nausea, vomiting, diarrhea, and constipation are common, especially in the first weeks. They usually improve with gradual dose titration. Rarer effects include pancreatitis, gallstones, and a statistical signal for thyroid C-cell tumors (observed in rodents, not confirmed in humans but listed as a precaution on the label).

The rebound problem. The most inconvenient data point for manufacturers: when the drug is discontinued, most patients regain about two-thirds of lost weight within 12 months. GLP-1 manages the satiety signal, it doesn't rewrite habits. Without a deep change in the relationship with food and physical activity, weight returns.

Tirzepatide: the dual agonist

If semaglutide was revolutionary, tirzepatide (Mounjaro/Zepbound) raised the bar further. Unlike semaglutide, which acts only on the GLP-1 receptor, tirzepatide is a dual agonist: it simultaneously activates GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors.

SURMOUNT trial results were even more pronounced: average weight loss of 20-26% at 72 weeks. This means that for the first time, a drug achieves results comparable to bariatric surgery — without the scalpel.

The side effect profile is similar to semaglutide, with nausea and gastrointestinal issues as the most frequent events. Long-term data remains limited, as it received approval more recently.

Retatrutide: the frontier

On the horizon looms retatrutide, a triple agonist (GLP-1, GIP, and glucagon receptor). Phase 2 trials showed weight losses of up to 24% at 48 weeks. Phase 3 data is expected for 2026-2027. If confirmed, it would represent yet another leap forward.

The muscle mass question

An often underestimated side effect of GLP-1 drugs concerns body composition. Weight loss is never just fat: a significant portion can be muscle mass. In semaglutide trials, approximately 30-40% of weight lost was lean mass.

This is a serious concern, especially in a longevity context. Muscle mass is the best predictor of mortality in older adults, as we've explored in our discussion of sarcopenia. Losing muscle to lose fat is a dangerous trade-off.

The solution? Resistance training during treatment is essential, not optional. Anyone taking GLP-1 drugs must follow a structured resistance program and adequate protein intake to minimize muscle loss.

"Ozempic face" and other visible signs

The term "Ozempic face" has entered common language to describe facial skin laxity that accompanies rapid weight loss. It's not an effect of the drug itself, but of facial subcutaneous fat loss combined with volume loss. It occurs with any rapid, significant weight loss, but the speed of GLP-1 results has made it particularly noticeable.

The gray market and its risks

Enormous demand and supply difficulties have created a dangerous parallel market. Online, you can find "generic" versions of semaglutide and tirzepatide produced by uncertified labs, often sold as "research peptides."

The risks are the same as documented for other unregulated peptides: contamination, incorrect dosing, wrong molecules. But in this case, the stakes are even higher because these drugs act on fundamental metabolic systems. A wrong dosage doesn't mean "it works a little less" — it can cause hypoglycemia, pancreatitis, or other serious adverse events.

The real role in longevity

Beyond weight loss, GLP-1 drugs are showing unexpected benefits. The SELECT trial demonstrated that semaglutide reduces major cardiovascular events (heart attack, stroke) by 20%, independent of weight loss. Effects on neurodegenerative diseases, fatty liver disease, kidney disease, and addictions are being studied.

It's possible that GLP-1 acts as a broad-spectrum geroprotector, reducing the systemic inflammation that drives many chronic diseases. But research is still in early stages for these indications.

A compass for navigation

If you're considering a GLP-1 drug, here's what you need to know.

These are real drugs, with solid clinical data and regulatory approvals. They are not experimental gray-area peptides. But this doesn't make them a magic solution.

They work best when accompanied by structural changes: balanced nutrition, strength training, stress management, and adequate sleep. Without these foundations, weight will return when you stop the medication.

Your doctor is the only valid interlocutor to evaluate whether you're an appropriate candidate. Self-administering products purchased online isn't optimization — it's an uncalculated risk.